Please login to the form below

Not currently logged in
Email:
Password:

Multiple approvals for Novartis' MS drug

Novartis has received approval in Switzerland and Australia for its MS drug Gilenya, and a recommendation from CHMP for its use in the EU

Novartis has received approval from Swissmedic, the Swiss Agency for therapeutic products, and the Australian Therapeutic Goods Administration (TGA) for Gilenya (fingolimod) 0.5 mg as a first-line, oral disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis (RRMS).

The Committee for Medicinal Products for Human Use (CHMP), an expert committee of the European Medicines Agency (EMA), has adopted a positive opinion and recommended the approval of Gilenya 0.5 mg. A UK licence is expected in the next few months.

Gilenya is already approved in the US and Russia and has been filed with health authorities worldwide.

"MS is an unpredictable condition. People with MS live with the uncertainty of not knowing when a relapse will next strike; causing distress and affecting work and family life. Some people recover from the relapses, others do not, which contributes to disability." said Dr Eli Silber, fingolimod clinical trial investigator and consultant neurologist who leads an MS service for South London based at King's College.  

The Gilenya approvals and CHMP opinion were based on data from a large clinical trial programme showing that Gilenya reduced relapses by 52 per cent at one year when compared with interferon beta-1a IM, an approved first-line DMT. The data also showed a 54 per cent reduction in relapses at two years compared with placebo.

The trial data also showed that patients receiving Gilenya had a 30 per cent lower risk of disability progression, confirmed after three months and a 37 per cent lower risk of disability progression, confirmed after six months. Gilenya has a well-studied safety and tolerability profile and has been tested on more than 4,000 clinical trial patients worldwide.

Gilenya works differently to any other MS treatment by controlling immune cells that mistakenly attack the brain and spinal cord. These cells (lymphocytes) are retained in the lymph nodes (glands) to prevent them from causing damage. 

MS affects around 100,000 people in the UK and around 2.5m people globally. It is typically diagnosed between 20-40 years of age, with women twice as likely to develop the condition than men. MS is potentially the most common cause of non-traumatic, neurological disability in young adults.

24th January 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...